Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPC-4326 (Bevirimat) in Treatment-Experienced HIV-1
NCT01026727Phase 2Terminated
- Sponsor
- Myrexis, Inc.
- Start
- Nov 2009
- Primary completion
- Jun 2010
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of bevirimat in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Myrexis, Inc. Primary endpoint: Proportion of subjects with a viral load <50 copies/mL at 24 weeks. Started Nov 2009; status: terminated.
02
Drugs
bevirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01026727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01026727.